Page 53 - JCTR-9-5

Iyngkaran et al. | Journal of Clinical and Translational Research 2023; 9(5): 347-356 355
2022;145:e895-1032. Muscle by Acetylcholine. Nature 1980;288:373-6.
[3] Roger VL. Epidemiology of Heart Failure. Circ Res [17] Macdonald P, Schyvens C, Winlaw D. The Role of Nitric
2013;113:646-59. Oxide in Heart Failure. Potential for Pharmacological
[4] Conrad N, Judge A, Tran J, Mohseni H, Hedgecott D, Intervention. Drugs Aging 1996;8:452-8.
Crespillo AP, et al. Temporal Trends and Patterns in Heart [18] Kubo SH, Rector TS, Bank AJ, Williams RE, Heifetz SM.
Failure Incidence: A Population-Based Study of 4 Million Endothelium-Dependent Vasodilation is Attenuated in
Individuals. Lancet 2018;391:572-80. Patients with Heart Failure. Circulation 1991;84:1589-96.
[5] Ziaeian B, Fonarow GC. Epidemiology and Aetiology of [19] Elkayam U, Khan S, Mehboob A, Ahsan N. Impaired
Heart Failure. Nat Rev Cardiol 2016;13:368-78. Endothelium-Mediated Vasodilation in Heart Failure:
[6] Savarese G, Lund LH. Global Public Health Burden of Clinical Evidence and the Potential for Therapy. J Card
Heart Failure. Card Fail Rev 2017;3:7-11. Fail 2002;8:15-20.
[7] Iyngkaran P, Majoni W, Cass A, Sanders P, Ronco C, [20] Yanagisawa M, Kurihara H, Kimura S, Tomobe Y,
Brady S, et al. Northern Territory Perspectives on Heart Kobayashi M, Mitsui Y, et al. A Novel Potent
Failure with Comorbidities-Understanding Trial Validity Vasoconstrictor Peptide Produced by Vascular Endothelial
and Exploring Collaborative Opportunities to Broaden the Cells. Nature 1988;332:411-5.
Evidence Base. Heart Lung Circ 2015;24:536-43. [21] Rajendran P, Rengarajan T, Thangavel J, Nishigaki Y,
[8] Fonarow GC, Stough WG, Abraham WT, Albert NM, Sakthisekaran D, Sethi G, et al. The Vascular Endothelium
Gheorghiade M, Greenberg BH, et al. Characteristics, and Human Diseases. Int J Biol Sci 2013;9:1057-69.
Treatments, and Outcomes of Patients with Preserved [22] Dulce RA, Kulandavelu S, Schulman IH, Fritsch J, Hare JM.
Systolic Function Hospitalized for Heart Failure: A Report Nitric Oxide Regulation of Cardiovascular Physiology and
from the OPTIMIZE-HF Registry. J Am Coll Cardiol Pathophysiology. Nitric Oxide Biology and Pathology.
2007;50:768-77. 3 ed. United States: Academic Press; 2017. p. 313-38.
rd
[9] Iyngkaran P, Thomas M. Bedside-to-Bench Translational [23] Förstermann U, Sessa WC. Nitric Oxide Synthases:
Research for Chronic Heart Failure: Creating an Agenda Regulation and Function. Eur Heart J 2012;33:829-37,
for Clients Who do not Meet Trial Enrollment Criteria. 837a-d.
Clin Med Insights Cardiol 2015;9:121-32. [24] Zuchi C, Tritto I, Carluccio E, Mattei C, Cattadori G,
[10] Al-Mohammad A. Hydralazine and Nitrates in the Ambrosio G. Role of Endothelial Dysfunction in Heart
Treatment of Heart Failure with Reduced Ejection Fraction. Failure. Heart Fail Rev 2020;25:21-30.
ESC Heart Fail 2019;6:878-83.
[11] Carson P, Ziesche S, Johnson G, Cohn JN. Racial Differences [25] Farah C, Michel LY, Balligand JL. Nitric Oxide Signalling
in Cardiovascular Health and Disease. Nat Rev Cardiol
in Response to Therapy for Heart Failure: Analysis of the 2018;15:292-316.
Vasodilator-Heart Failure Trials. Vasodilator-Heart Failure
Trial Study Group. J Card Fail 1999;5:178-87. [26] Segers VF, Brutsaert DL, De Keulenaer GW. Cardiac
[12] Exner DV, Dries DL, Domanski MJ, Cohn JN. Lesser Remodeling: Endothelial Cells have more to Say than Just
no. Front Physiol 2018;9:382.
Response to Angiotensin-Converting-Enzyme Inhibitor
Therapy in Black as Compared with White Patients with Left [27] Tsutsui H, Kinugawa S, Matsushima S. Oxidative Stress
Ventricular Dysfunction. N Engl J Med 2001;344:1351-7. and Heart Failure. Am J Physiol Heart Circ Physiol
[13] Khazanie P, Liang L, Curtis LH, Butler J, Eapen ZJ, 2011;301:H2181-90.
Heidenreich PA, et al. Clinical Effectiveness of [28] Keller-Ross ML, Larson M, Johnson BD. Skeletal Muscle
Hydralazine-Isosorbide Dinitrate Therapy in Patients with Fatigability in Heart Failure. Front Physiol 2019;10:129.
Heart Failure and Reduced Ejection Fraction: Findings [29] Alem MM. Endothelial Dysfunction in Chronic Heart
from the Get with the Guidelines-Heart Failure Registry. Failure: Assessment, Findings, Significance, and Potential
Circ Heart Fail 2016;9:e002444. Therapeutic Targets. Int J Mol Sci 2019;20:3198.
[14] Ziaeian B, Fonarow GC, Heidenreich PA. Clinical [30] Hafen BB, Burns B. Physiology, smooth muscle. In:
Effectiveness of Hydralazine-Isosorbide Dinitrate in StatPearls. Treasure Island, FL: StatPearls Publishing; 2022.
African-American Patients with Heart Failure. JACC [31] Zhuge Y, Zhang J, Qian F, Wen Z, Niu C, Xu K, et al. Role
Heart Fail 2017;5:632-9. of Smooth Muscle Cells in Cardiovascular Disease. Int J
[15] Brewster LM. Underuse of Hydralazine and Isosorbide Biol Sci 2020;16:2741-51.
Dinitrate for Heart Failure in Patients of African Ancestry: [32] Song T, Manoharan P, Millay DP, Koch SE, Rubinstein J,
A Cross-European Survey. ESC Heart Fail 2019;6:487-98. Heiny JA, et al. Dilated Cardiomyopathy-Mediated Heart
[16] Furchgott RF, Zawadzki JV. The Obligatory Role of Failure Induces a Unique Skeletal Muscle Myopathy with
Endothelial Cells in the Relaxation of Arterial Smooth Inflammation. Skelet Muscle 2019;9:4.

DOI: http://dx.doi.org/10.18053/jctres.09.202305.23-00010